14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
XOMA vs MYGN
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
XOMA vs MYGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
XOMA Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 9–1 Matrix Metrics)
XOMA Overall Winner
6-Pillar Tally: XOMA 3 – 3 MYGN
Matrix Metrics: XOMA 9 – 1 MYGN
As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas MYGN carries 45.9/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin).
Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. MYGN 45.9/100 HOLD) and 0.68β · 37% Vol risk profile, whereas MYGN leads top-line expansion (-1.5% YoY revenue growth, 1.40x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
XOMA
NASDAQ
Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
Market Cap
$781.8M
TTM Revenue
$49M
Forward P/E
21.5x
Beta / 30D Vol
0.68β · 37% Vol
Unified Composite Score
55.8 / 100
HOLD
Tech 40.0
Fund 52.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06
MYGN
NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
Market Cap
$544.8M
TTM Revenue
$804M
Forward P/E
54.0x
Beta / 30D Vol
0.69β · 122% Vol
Unified Composite Score
45.9 / 100
HOLD
Tech 30.0
Fund 41.0
Flow 56.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.2% over 20 days), RSI 52
RSI-14: 52.0 · SMA20: $5.94 · SMA50: $4.80
6-Pillar Scorecard Institutional Category Breakdown (XOMA 3 – 3 MYGN)
Columns: Metric · XOMA · MYGN
1. Valuation Multiples
XOMA
Forward P/E
21.5x
54.0x
Trailing P/E
28.2x
54.0x
PEG Ratio
N/M
1.40x
EV / Revenue
16.1x
0.8x
2. Growth & Scale
MYGN
Revenue Growth (YoY)
-22.6%
-1.5%
Earnings Growth (YoY)
+207.9%
+0.0%
TTM Revenue (USD)
$49M
$804M
Market Cap
$781.8M
$544.8M
3. Profitability & Quality
XOMA
Gross Margin
99.0%
68.3%
Operating Margin
-3.9%
-13.3%
Net Profit Margin
69.6%
-16.1%
Return on Equity (ROE)
34.2%
-40.2%
4. Balance Sheet & Cash Flow
XOMA
Cash Generation (TTM)
$8.3M EBITDA
-$38M
Cash Flow Margin
17.1% EBITDA Mgn
-4.7%
Net Cash / Leverage
$7.79 Book/Sh · 34.2% ROE
$102M Net Debt (0.78x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MYGN
Options Structure Phase
UNCLASSIFIED
SURGE
Current IV / %ile
101.5% (100th %ile)
124.6% (22nd %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat
MYGN
OpEx & R&D Intensity
N/A
81.6% of Rev ($656M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: XOMA (9) vs MYGN (1)
Institutional Metric
XOMA
MYGN
Criterion
Row Edge
Market Capitalization
Scale
$781.8M
$544.8M
Larger Scale
XOMA
Trailing P/E Ratio
Valuation
28.2x
54.0x
Lower Multiple
XOMA
Forward P/E Ratio
Valuation
21.5x
54.0x
Lower Multiple
XOMA
Revenue Growth (YoY)
Growth
-22.6%
-1.5%
Higher Growth
MYGN
Operating Margin (TTM)
Profitability
-3.9%
-13.3%
Higher Margin
XOMA
Net Profit Margin
Profitability
69.6%
-16.1%
Higher Margin
XOMA
Return on Equity (ROE)
Capital Efficiency
34.2%
-40.2%
Higher ROE
XOMA
52-Week Range Position
Momentum
78% ($22–$45)
53% ($3–$8)
Stronger Trend
XOMA
Beta / 30D Volatility
Risk Regime
0.68β · 37% Vol
0.69β · 122% Vol
Lower Realized Risk
XOMA
Unified Institutional Score
Composite Signal
55.8 / 100 (HOLD)
45.9 / 100 (HOLD)
Higher Composite
XOMA
Trailing 12M Revenue (USD)
Operating Scale
$49M
$804M
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.0%
68.3%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.1x EV/Rev
1.40x PEG · 0.8x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE)
-$38M ($102M Net Debt (0.78x D/E))
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
MYGN +36.09 pp
XOMA:
-3.81%
·
MYGN:
+32.28%
3M Horizon
MYGN +25.37 pp
XOMA:
+9.34%
·
MYGN:
+34.71%
6M Horizon
XOMA +44.93 pp
XOMA:
+34.26%
·
MYGN:
-10.67%
1Y Horizon
XOMA +32.32 pp
XOMA:
+24.6%
·
MYGN:
-7.72%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs MYGN. Trailing 12-month operating profitability (XOMA -3.9% vs MYGN -13.3%) and valuation multiples (XOMA 21.5x vs MYGN 54.0x Forward P/E) are benchmarked directly in Pillar 4 below.
XOMA ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $49M
Gross Margin 99.0%
Op. Margin -3.9%
ROE / Fwd P/E 34.2% · 21.5x
MYGN ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $804M
Gross Margin 68.3%
Op. Margin -13.3%
ROE / Fwd P/E -40.2% · 54.0x
XOMA
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
101.5%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
MYGN
SURGE
12d in phase · OBV DISTRIBUTION
Current IV
124.6%
IV Percentile
22nd %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
XOMA Moat Profile
Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
MYGN Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $544.8M market capitalization and -13.3% operating margin.
OpEx & R&D Reinvestment
81.6% of Rev ($656M)
90D Engineering Disclosures
0 Published
Investor FAQ XOMA vs MYGN Key Questions & Quantitative Answers
Is XOMA or MYGN a better stock to buy right now?
As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas MYGN carries 45.9/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin). Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. MYGN 45.9/100 HOLD) and 0.68β · 37% Vol risk profile, whereas MYGN leads top-line expansion (-1.5% YoY revenue growth, 1.40x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Does XOMA or MYGN have stronger revenue and earnings growth?
MYGN leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with MYGN at -1.5% YoY revenue growth and +0.0% YoY earnings growth on $804M TTM revenue (68.3% gross margin, -13.3% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus $804M for MYGN. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus 81.6% of Rev ($656M) (0 disclosures) for MYGN.
Is XOMA or MYGN cheaper on valuation?
XOMA screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas MYGN trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.40x PEG, and 0.8x EV/Revenue (-4.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus MYGN (-40.2% ROE) capital efficiency.
How is options market volatility positioned on XOMA vs MYGN?
In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, MYGN carries 124.6% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.69β · 122% Vol realized risk).
XOMA Royalty Corporation Common Stock (XOMA) Research Suite
Myriad Genetics Inc (MYGN) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.